KRMD تصريحات هيئة الأوراق المالية والبورصات - KORU Medical Systems, Inc.- التقرير السنوي، بيان التوكيل، نشرة الإصدار

الإحصائيات الأساسية

CIK

704440

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to KORU Medical Systems, Inc.

SEC Filings (Chronological Order)

توفر هذه الصفحة قائمة كاملة ومرتبة ترتيبًا زمنيًا لتصريحات هيئة الأوراق المالية والبورصات، باستثناء تصريحات الملكية التي نقدمها في مكان آخر.

August 13, 2025	S-8	As filed with the Securities and Exchange Commission on August 12, 2025 As filed with the Securities and Exchange Commission on August 12, 2025 Registration No.
August 13, 2025	EX-FILING FEES	CALCULATION OF FILING FEE TABLES KORU Medical Systems, Inc. Table 1: Newly Registered and Carry Forward Securities Ex-Filing Fees CALCULATION OF FILING FEE TABLES S-8 KORU Medical Systems, Inc. Table 1: Newly Registered and Carry Forward Securities Line Item Type Security Type Security Class Title Notes Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities Fees to be Paid Equity Common sto
August 6, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 6, 2025 KORU Medical Systems, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 6, 2025 KORU Medical Systems, Inc.
August 6, 2025	EX-10	Restricted Stock Agreement dated as of July 28, 2025 between KORU Medical Systems, Inc. and Adam Kalbermatten EXHIBIT 10.3 KORU MEDICAL SYSTEMS, INC. RESTRICTED STOCK AGREEMENT THIS RESTRICTED STOCK AGREEMENT (this “Agreement”), dated as of July 28, 2025 (the “Effective Date”), is made by and between KORU Medical Systems, Inc., a Delaware corporation, having its principal place of business at 100 Corporate Drive, Mahwah, NJ 07430 (the “Company”), and Adam Kalbermatten, an individual residing at [address]
August 6, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2025 or [] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 0-12305 KORU ME
August 6, 2025	EX-10	Nonqualified Stock Option Award dated as of August 1, 2025 between KORU Medical Systems, Inc. and Adam Kalbermatten EXHIBIT 10.2 KORU MEDICAL SYSTEMS, INC. NONQUALIFIED STOCK OPTION AWARD This NONQUALIFIED STOCK OPTION AWARD (this “Agreement”), dated as of August 1, 2025 (the “Date of Grant”), is delivered by KORU Medical Systems, Inc., a Delaware corporation (the “Company”), to Adam Kalbermatten, an individual (the “Grantee”). The Compensation Committee of the Board of Directors of the Company (the “Committee”
August 6, 2025	EX-10	Employment Agreement dated as of June 30, 2025 between KORU Medical Systems, Inc. and Adam Kalbermatten EXHIBIT 10.1 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this “Agreement”) effective as of June 30, 2025, is made by and between KORU Medical Systems, Inc., a Delaware corporation, having its principal place of business at 100 Corporate Drive, Mahwah, NJ 07430 (the “Company”), and Adam Kalbermatten, an individual having a domicile at [address] (“Employee” or “Executive”). WHEREAS, the Company
August 6, 2025	EX-99	KORU MEDICAL SYSTEMS ANNOUNCES Q2 2025 FINANCIAL RESULTS, INCLUDING RECORD DOUBLE-DIGIT REVENUE, AND RAISES 2025 REVENUE GUIDANCE EXHIBIT 99.1 KORU MEDICAL SYSTEMS ANNOUNCES Q2 2025 FINANCIAL RESULTS, INCLUDING RECORD DOUBLE-DIGIT REVENUE, AND RAISES 2025 REVENUE GUIDANCE MAHWAH, NJ – August 6, 2025 – KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcu
May 15, 2025	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 14, 2025 KORU Medical Systems, Inc.
May 7, 2025	EX-99	KORU MEDICAL SYSTEMS ANNOUNCES RECORD Q1 2025 FINANCIAL RESULTS AND RAISES 2025 REVENUE GUIDANCE EXHIBIT 99.1 KORU MEDICAL SYSTEMS ANNOUNCES RECORD Q1 2025 FINANCIAL RESULTS AND RAISES 2025 REVENUE GUIDANCE MAHWAH, NJ – May 7, 2025 – KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today re
May 7, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2025 or [] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 0-12305 KORU M
May 7, 2025	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 7, 2025 KORU Medical Systems, Inc.
April 7, 2025	8-K	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 3, 2025 KORU Medical Systems, Inc.
April 4, 2025	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
April 4, 2025	8-K	Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 31, 2025 KORU Medical Systems, Inc.
April 4, 2025	EX-10	Amendment No. 1 to Loan and Security Agreement dated as of March 31, 2025 by and between KORU Medical Systems, Inc. and HSBC Ventures USA Inc. EXHIBIT 10.1 AMENDMENT NO. 1 TO LOAN AND SECURITY AGREEMENT This Amendment No. 1 to Loan and Security Agreement (this “Amendment”) is dated as of March 31, 2025, by and between KORU MEDICAL SYSTEMS, INC., a Delaware corporation (“Borrower”) and HSBC VENTURES USA INC., a Delaware corporation (“Bank”). 1. Reference is made to that certain Loan and Security Agreement dated as of March 8, 2024, by and
March 12, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-12305 KORU MEDICAL SYSTEMS, INC.
March 12, 2025	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables FORM S-8 (Form Type) KORU Medical Systems, Inc.
March 12, 2025	S-8	As filed with the Securities and Exchange Commission on March 12, 2025 As filed with the Securities and Exchange Commission on March 12, 2025 Registration No.
March 12, 2025	EX-10	Form of Performance Share Unit Award Agreement EXHIBIT 10.5 KORU MEDICAL SYSTEMS, INC. 2024 Omnibus Equity Incentive Plan PERFORMANCE SHARE UNIT AWARD AGREEMENT Pursuant to this Performance Share Unit Award Agreement (this “Award Agreement”), and subject to the terms and conditions herein and in the KORU Medical Systems, Inc. 2024 Omnibus Equity Incentive Plan (the “Plan”), KORU Medical Systems, Inc. (the “Company”) grants an Award of performa
March 12, 2025	EX-10	Form of Restricted Stock Unit Award Agreement EXHIBIT 10.6 KORU MEDICAL SYSTEMS, INC. 2024 Omnibus Equity Incentive Plan Restricted Stock Unit AWARD Agreement Pursuant to this Restricted Stock Unit Award Agreement (this “Award Agreement”), and subject to the terms and conditions herein and in the KORU Medical Systems, Inc. 2024 Omnibus Equity Incentive Plan (the “Plan”), KORU Medical Systems, Inc. (the “Company”) grants an Award of restricted
March 12, 2025	EX-97	Clawback Policy EXHIBIT 97 KORU MEDICAL SYSTEMS, INC. CLAWBACK POLICY The Board of Directors (the “Board”) of KORU Medical Systems, Inc. (the “Company”) believes that it is in the best interests of the Company and its shareholders to adopt this Clawback Policy (the “Policy”), which provides for the recovery of certain incentive compensation in the event of an Accounting Restatement (as defined below). This Policy
March 12, 2025	EX-10	Non-Employee Director Compensation EXHIBIT 10.7 KORU Medical Systems, Inc. Summary of Non-Employee Director Compensation The Board of Directors of KORU Medical Systems, Inc. (the “Company”) has approved the following compensation for its non-employee directors effective with approval of the Company’s 2021 Omnibus Equity Incentive Plan by its shareholders on May 18, 2021. In each case payable quarterly on the day following the end o
March 12, 2025	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 12, 2025 KORU Medical Systems, Inc.
March 12, 2025	EX-19	KORU Medical Systems, Inc. Insider Trading Policy EXHIBIT 19 January 2022 KORU MEDICAL SYSTEMS, INC. POLICY ON INSIDER TRADING It is very important that all directors, officers and employees of KORU Medical Systems, Inc. (the “Company”) be familiar with the Company’s policy on trading in securities of the Company or entities with which the Company does business. Thus, each of you is asked to read this Policy on Insider Trading (this “Policy”), ca
March 12, 2025	EX-99	KORU Medical Systems Announces Fourth Quarter and Full Year 2024 Financial Results with Record Revenues and Gross Profit; Issues Full Year 2025 Guidance EXHIBIT 99.1 KORU Medical Systems Announces Fourth Quarter and Full Year 2024 Financial Results with Record Revenues and Gross Profit; Issues Full Year 2025 Guidance MAHWAH, NJ – March 12, 2025 – KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-cen
March 12, 2025	S-8 POS	As filed with the Securities and Exchange Commission on March 12, 2025 As filed with the Securities and Exchange Commission on March 12, 2025 Registration No.
February 14, 2025	EX-1	JOINT FILING AGREEMENT Exhibit A JOINT FILING AGREEMENT The Undersigned agree that the statement on Schedule 13G with respect to the common stock of KORU Medical Systems, Inc.
January 21, 2025	EX-99	JOINT FILING AGREEMENT Exhibit 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing with the Securities and Exchange Commission on behalf of each of them of Schedule 13D/A, to which this Exhibit 1 is attached (including amendments thereto) with respect to certain shares of common stock of Repro Med Systems, Inc.
January 13, 2025	8-K	Regulation FD Disclosure, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 13, 2025 KORU Medical Systems, Inc.
January 13, 2025	EX-99	Exhibit 99.1 Exhibit 99.1
January 13, 2025	EX-99	KORU Medical Systems Reports Preliminary Fourth Quarter and Full Year 2024 Results; Achieves Record Full Year and Quarterly Revenues; Positive Cash Flow for the Fourth Quarter EXHIBIT 99.1 KORU Medical Systems Reports Preliminary Fourth Quarter and Full Year 2024 Results; Achieves Record Full Year and Quarterly Revenues; Positive Cash Flow for the Fourth Quarter MAHWAH, NJ – January 13, 2025 – KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of inn
November 14, 2024	EX-99.A	JOINT FILING UNDERTAKING EX-99.A 2 d845615dex99a.htm EX-99.A EXHIBIT A JOINT FILING UNDERTAKING The undersigned, being authorized thereunto, hereby execute this agreement as an exhibit to this Schedule 13G to evidence the agreement of the below-named parties, in accordance with rules promulgated pursuant to the Securities Exchange Act of 1934, to file this Schedule, as it may be amended, jointly on behalf of each of such
November 14, 2024	SC 13G/A	KRMD / KORU Medical Systems, Inc. / Topline Capital Management, LLC - SC 13G/A Passive Investment SC 13G/A 1 d845615dsc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Koru Medical Systems, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 759910102 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of Statement) Check the appropriate box to d
November 13, 2024	SC 13G/A	KRMD / KORU Medical Systems, Inc. / Archon Capital Management LLC Passive Investment SC 13G/A 1 d1151568513g-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* KORU Medical Systems, Inc. (Name of Issuer) Common Stock, $0.01 Par Value (Title of Class of Securities) 759910102 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate
November 13, 2024	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 13, 2024 KORU Medical Systems, Inc.
November 13, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2024 or [] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 0-12305 KO
November 13, 2024	EX-99	KORU MEDICAL SYSTEMS, INC. ANNOUNCES 2024 Q3 FINANCIAL RESULTS, THIRD CONSECUTIVE QUARTER OF DOUBLE-DIGIT GROWTH; RAISES FULL YEAR 2024 GUIDANCE EXHIBIT 99.1 KORU MEDICAL SYSTEMS, INC. ANNOUNCES 2024 Q3 FINANCIAL RESULTS, THIRD CONSECUTIVE QUARTER OF DOUBLE-DIGIT GROWTH; RAISES FULL YEAR 2024 GUIDANCE MAHWAH, NJ – November 13, 2024 – KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric
August 21, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 15, 2024 KORU Medical Systems, Inc.
August 21, 2024	EX-10	Form of Performance Stock Unit Award Agreement EXHIBIT 10.3 KORU MEDICAL SYSTEMS, INC. 2024 Omnibus Equity Incentive Plan PERFORMANCE SHARE UNIT AWARD AGREEMENT Pursuant to this Performance Share Unit Award Agreement (this “Award Agreement”), and subject to the terms and conditions herein and in the KORU Medical Systems, Inc. 2024 Omnibus Equity Incentive Plan (the “Plan”), KORU Medical Systems, Inc. (the “Company”) grants an Award of performa
August 21, 2024	EX-10	KORU Medical Systems, Inc. Long-Term Incentive Program EXHIBIT 10.1 KORU MEDICAL SYSTEMS, INC. LONG-TERM INCENTIVE PROGRAM (AS OF August 15, 2024) The KORU Medical Systems, Inc. Long-Term Incentive Program (the “LTIP”) was adopted by the Compensation Committee of the Board of Directors (the “Committee”) to set forth the terms and conditions of the long-term incentive program of the Company, the purpose of which is to incentivize the retention and perf
August 21, 2024	EX-10	Form of Restricted Stock Unit Award Agreement EXHIBIT 10.2 KORU MEDICAL SYSTEMS, INC. 2024 Omnibus Equity Incentive Plan RESTRICTED STOCK UNIT AWARD AGREEMENT Pursuant to this Restricted Stock Unit Award Agreement (this “Award Agreement”), and subject to the terms and conditions herein and in the KORU Medical Systems, Inc. 2024 Omnibus Equity Incentive Plan (the “Plan”), KORU Medical Systems, Inc. (the “Company”) grants an Award of restricted
August 21, 2024	EX-10	Form of Nonqualified Stock Option Award Agreement EXHIBIT 10.4 KORU MEDICAL SYSTEMS, INC. 2024 OMNIBUS EQUITY INCENTIVE PLAN NONQUALIFIED STOCK OPTION AWARD This NONQUALIFIED STOCK OPTION AWARD (this “Agreement”), dated as of , (the “Date of Grant”), is delivered by KORU Medical Systems, Inc., a Delaware corporation (the “Company”), to (the “Grantee”). The Company’s 2024 Omnibus Equity Incentive Plan (the “Plan”) provides for the grant of nonqual
August 7, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2024 or [] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 0-12305 KORU ME
August 7, 2024	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 7, 2024 KORU Medical Systems, Inc.
August 7, 2024	EX-99	KORU MEDICAL SYSTEMS, INC. ANNOUNCES 2024 Q2 FINANCIAL RESULTS, A RECORD QUARTER WITH 22% REVENUE GROWTH; RAISES FULL YEAR 2024 GUIDANCE EXHIBIT 99.1 KORU MEDICAL SYSTEMS, INC. ANNOUNCES 2024 Q2 FINANCIAL RESULTS, A RECORD QUARTER WITH 22% REVENUE GROWTH; RAISES FULL YEAR 2024 GUIDANCE MAHWAH, NJ – August 7, 2024 – KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volum
July 24, 2024	EX-10	Amended and Restated Employment Agreement effective as of July 18, 2024 between KORU Medical Systems, Inc. and Christopher Pazdan EXHIBIT 10.1 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”), effective as of July 18, 2024, is made by and between KORU Medical Systems, Inc., a Delaware corporation, having its principal place of business at 100 Corporate Drive, Mahwah, NJ 07430 (the “Company”), and Christopher Pazdan, an individual having a domicile at ****************
July 24, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 24, 2024 KORU Medical Systems, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 24, 2024 KORU Medical Systems, Inc.
July 10, 2024	S-8 POS	As filed with the Securities and Exchange Commission on July 9, 2024 As filed with the Securities and Exchange Commission on July 9, 2024 Registration No.
July 10, 2024	S-8	As filed with the Securities and Exchange Commission on July 9, 2024 As filed with the Securities and Exchange Commission on July 9, 2024 Registration No.
July 10, 2024	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) KORU Medical Systems, Inc.
June 3, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 3, 2024 KORU Medical Systems, I UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 3, 2024 KORU Medical Systems, Inc.
June 3, 2024	EX-99	EXHIBIT 16.1 EXHIBIT 16.1 June 3, 2024 Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Commissioners: We have read the Company’s statements included under Item 4.01(a) of its Current Report on Form 8-K dated June 3, 2024 (the “Form 8-K”), and we agree with such statements. Very truly yours, /s/ McGrail Merkel Quinn & Associates, P.C. Scranton, Pennsylvania
May 23, 2024	EX-99.A	JOINT FILING UNDERTAKING EX-99.A 2 d663401dex99a.htm EX-99.A EXHIBIT A JOINT FILING UNDERTAKING The undersigned, being authorized thereunto, hereby execute this agreement as an exhibit to this Schedule 13G to evidence the agreement of the below-named parties, in accordance with rules promulgated pursuant to the Securities Exchange Act of 1934, to file this Schedule, as it may be amended, jointly on behalf of each of such
May 23, 2024	SC 13G	KRMD / KORU Medical Systems, Inc. / Topline Capital Management, LLC - SC 13G Passive Investment SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.) Koru Medical Systems, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 759910102 (CUSIP Number) May 13, 2024 (Date of Event Which Requires Filing of Statement) Check the appropriate box to designate the rule pursuant to which this
May 14, 2024	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 9, 2024 KORU MEDICAL SYSTEMS, INC.
May 1, 2024	EX-99	KORU MEDICAL SYSTEMS, INC. ANNOUNCES 2024 FIRST QUARTER FINANCIAL RESULTS DELIVERING DOUBLE-DIGIT REVENUE GROWTH EXHIBIT 99.1 KORU MEDICAL SYSTEMS, INC. ANNOUNCES 2024 FIRST QUARTER FINANCIAL RESULTS DELIVERING DOUBLE-DIGIT REVENUE GROWTH MAHWAH, NJ – May 1, 2024 – KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion sol
May 1, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2024 or [] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 0-12305 KORU M
May 1, 2024	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 1, 2024 KORU Medical Systems, Inc.
April 11, 2024	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 8, 2024 KORU Medical Systems, Inc.
April 11, 2024	EX-99	KORU Medical Systems Announces Successful Appeal in EU Notified Body Review EXHIBIT 99.1 KORU Medical Systems Announces Successful Appeal in EU Notified Body Review MAHWAH, NJ – April 11, 2024 – KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced a successf
March 28, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
March 18, 2024	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [X] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
March 13, 2024	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 8, 2024 KORU Medical Systems, Inc.
March 13, 2024	EX-10	Stock Purchase Warrant issued to HSBC Ventures USA Inc. issued on March 8, 2024 Exhibit 10.2 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 6.3 AND 6.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTA
March 13, 2024	EX-99	KORU MEDICAL SYSTEMS, INC. ANNOUNCES 2023 FOURTH QUARTER, FULL YEAR FINANCIAL RESULTS, AND 2024 GUIDANCE EXHIBIT 99.1 KORU MEDICAL SYSTEMS, INC. ANNOUNCES 2023 FOURTH QUARTER, FULL YEAR FINANCIAL RESULTS, AND 2024 GUIDANCE MAHWAH, NJ – March 13, 2024 – KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solution
March 13, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-12305 KORU MEDICAL SYSTEMS, INC.
March 13, 2024	EX-10	Loan and Security Agreement dated as of March 8, 2024 by and between KORU Medical Systems, Inc. and HSBC Ventures USA Inc. Exhibit 10.1 LOAN AND SECURITY AGREEMENT dated as of March 8, 2024 between KORU MEDICAL SYSTEMS, INC., as Borrower and HSBC VENTURES USA INC., as Bank This LOAN AND SECURITY AGREEMENT (this “Agreement”) is dated as of March 8, 2024 (the “Effective Date”) by and between KORU MEDICAL SYSTEMS, INC., a Delaware corporation (“Borrower”) and HSBC VENTURES USA INC. (“Bank”), and provides the terms on whi
February 14, 2024	SC 13G	KRMD / KORU Medical Systems, Inc. / First Light Asset Management, LLC - SCHEDULE FILED TO REPORT ACQUISITION OF BENEFICIAL OWNERSHIP Passive Investment SC 13G 1 krmd-sc13g123123.htm SCHEDULE FILED TO REPORT ACQUISITION OF BENEFICIAL OWNERSHIP UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* (Amendment) KORU Medical Systems, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 759910102 (CUSIP Number) December 31, 2023 (Date of Event Which
February 13, 2024	SC 13G/A	KRMD / KORU Medical Systems, Inc. / Archon Capital Management LLC Passive Investment SC 13G/A 1 d1097198413g-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* KORU Medical Systems, Inc. (Name of Issuer) Common Stock, $0.01 Par Value (Title of Class of Securities) 759910102 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate
January 2, 2024	SC 13D/A	KRMD / KORU Medical Systems, Inc. / Horton Capital Partners, LLC - SC 13D/A Activist Investment SC 13D/A 1 d692827dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 10) KORU Medical Systems, Inc. (Name of Issuer) Common Stock, Par Value $0.01 Per Share (Title of Class of Securities) 759910102 (CUSIP Number) JOSEPH M. MANKO, JR. HORTON CAPITAL PARTNERS, LLC 1717 Arch Street, Suite 3
January 2, 2024	EX-99.1	JOINT FILING AGREEMENT EX-99.1 2 d692827dex991.htm EXHIBIT 1 Exhibit 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing with the Securities and Exchange Commission on behalf of each of them of Schedule 13D/A, to which this Exhibit 1 is attached (including amendments thereto) with respect to certain shares
November 8, 2023	EX-10	Employment Agreement effective as of November 6, 2023 between KORU Medical Systems, Inc. and Kenneth Miller Exhibit 10.1 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this “Agreement”) effective as of November 6, 2023, is made by and between KORU Medical Systems, Inc., a Delaware corporation, having its principal place of business at 100 Corporate Drive, Mahwah, NJ 07430 (the “Company”), and Kenneth Miller, an individual having a domicile at [address] (“Employee”). WHEREAS, the Company desires to empl
November 8, 2023	EX-99	KORU MEDICAL SYSTEMS, INC. ANNOUNCES 2023 THIRD QUARTER FINANCIAL RESULTS and updates full year 2023 outlook EXHIBIT 99.1 KORU MEDICAL SYSTEMS, INC. ANNOUNCES 2023 THIRD QUARTER FINANCIAL RESULTS and updates full year 2023 outlook MAHWAH, NJ – November 8, 2023 – KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty infusion solutions that imp
November 8, 2023	EX-10	Form of Non-Qualified Stock Option Agreement Exhibit 10.3 Certain information identified by [***] has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the registrant if publicly disclosed. KORU MEDICAL SYSTEMS, INC. NONQUALIFIED STOCK OPTION AWARD This NONQUALIFIED STOCK OPTION AWARD (this “Agreement”), dated as of November 15, 2023 (the “Date of Grant”), is delivered by KORU
November 8, 2023	EX-99	KORU MEDICAL SYSTEMS, INC. APPOINTS KEN MILLER AS CHIEF COMMERCIAL OFFICER EXHIBIT 99.3 KORU MEDICAL SYSTEMS, INC. APPOINTS KEN MILLER AS CHIEF COMMERCIAL OFFICER MAHWAH, NJ – November 8, 2023 – KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty subcutaneous infusion solutions that improve quality of life
November 8, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2023 or [] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 0-12305 KO
November 8, 2023	EX-99	KORU MEDICAL SYSTEMS, INC. RECEIVES FDA 510(k) CLEARANCE FOR FREEDOM60® INFUSION SYSTEM WITH HIZENTRA® 50 ML PREFILLED SYRINGES EXHIBIT 99.2 KORU MEDICAL SYSTEMS, INC. RECEIVES FDA 510(k) CLEARANCE FOR FREEDOM60® INFUSION SYSTEM WITH HIZENTRA® 50 ML PREFILLED SYRINGES MAHWAH, NJ – NOVEMBER 7, 2023 – KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty subcutan
November 8, 2023	EX-10	Form of Non-Qualified Stock Option Agreement Exhibit 10.2 KORU MEDICAL SYSTEMS, INC. NONQUALIFIED STOCK OPTION AWARD This NONQUALIFIED STOCK OPTION AWARD (this “Agreement”), dated as of November 15, 2023 (the “Date of Grant”), is delivered by KORU Medical Systems, Inc., a New York corporation (the “Company”), to Kenneth Miller (the “Grantee”). The Compensation Committee of the Board of Directors of the Company (the “Committee”) has decided t
November 8, 2023	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 6, 2023 KORU Medical Systems, Inc.
October 4, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 28, 2023 KORU MEDICAL SYST UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 28, 2023 KORU MEDICAL SYSTEMS, INC.
October 4, 2023	EX-99	KORU MEDICAL SYSTEMS, INC. ANNOUNCES APPOINTMENT OF EDWARD WHOLIHAN TO ITS BOARD OF DIRECTORS EXHIBIT 99.1 KORU MEDICAL SYSTEMS, INC. ANNOUNCES APPOINTMENT OF EDWARD WHOLIHAN TO ITS BOARD OF DIRECTORS MAHWAH, NJ – October 4, 2023 – KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty subcutaneous infusion solutions that improv
August 9, 2023	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 9, 2023 KORU Medical Systems, Inc.
August 9, 2023	EX-99	KORU MEDICAL SYSTEMS, INC. ANNOUNCES 2023 SECOND QUARTER FINANCIAL RESULTS AND UPDATES FULL YEAR 2023 OUTLOOK EXHIBIT 99.1 KORU MEDICAL SYSTEMS, INC. ANNOUNCES 2023 SECOND QUARTER FINANCIAL RESULTS AND UPDATES FULL YEAR 2023 OUTLOOK MAHWAH, NJ – August 9, 2023 – KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty infusion solutions that impr
August 9, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2023 or [] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 0-12305 KORU ME
August 2, 2023	EX-99	KORU MEDICAL SYSTEMS, INC. ANNOUNCES PRELIMINARY SECOND QUARTER 2023 REVENUES AND PROVIDES BUSINESS, OUTLOOK AND EXECUTIVE UPDATES EXHIBIT 99.1 KORU MEDICAL SYSTEMS, INC. ANNOUNCES PRELIMINARY SECOND QUARTER 2023 REVENUES AND PROVIDES BUSINESS, OUTLOOK AND EXECUTIVE UPDATES MAHWAH, NJ – August 2, 2023 – KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty subcuta
August 2, 2023	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 27, 2023 KORU Medical Systems, Inc.
August 2, 2023	EX-10	First Amendment to Employment Agreement effective as of August 1, 2023 between Thomas Adams and KORU Medical Systems, Inc. EXHIBIT 10.1 FIRST AMENDMENT TO EMPLOYMENT AGREEMENT THIS FIRST AMENDMENT TO EMPLOYMENT AGREEMENT (this “First Amendment”) is made and entered into as of August 1, 2023 (the “Effective Date”) by and between KORU Medical Systems, Inc., a Delaware corporation (the “Company”), and Thomas Adams (“Employee”). WHEREAS, the Company entered into an Employment Agreement with Employee dated October 18, 2021
July 18, 2023	S-8	As filed with the Securities and Exchange Commission on July 18, 2023 As filed with the Securities and Exchange Commission on July 18, 2023 Registration No.
July 18, 2023	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables FORM S-8 (Form Type) KORU Medical Systems, Inc.
June 27, 2023	EX-10	Form of Individual Stock Option Agreement EXHIBIT 10.2 KORU MEDICAL SYSTEMS, INC. NONQUALIFIED STOCK OPTION AWARD This NONQUALIFIED STOCK OPTION AWARD (this “Agreement”), dated as of July 15, 2023 (the “Date of Grant”), is delivered by KORU Medical Systems, Inc., a New York corporation (the “Company”), to Andrew LaFrence (the “Grantee”). The Compensation Committee of the Board of Directors of the Company (the “Committee”) has decided to m
June 27, 2023	EX-10	Employment Agreement dated as of June 22, 2023 by and between the KORU Medical Systems, Inc. and Andrew D. C. LaFrence EXHIBIT 10.1 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this “Agreement”) effective as of June 22, 2023, is made by and between KORU Medical Systems, Inc., a Delaware corporation, having its principal place of business at 100 Corporate Drive, Mahwah, NJ 07430 (the “Company”), and Andrew D. C. LaFrence, an individual having a domicile at [address] (“Employee”). WHEREAS, the Company desires to
June 27, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 22, 2023 KORU Medical Systems, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 22, 2023 KORU Medical Systems, Inc.
June 27, 2023	EX-99	KORU MEDICAL SYSTEMS, INC. NAMES ANDREW LAFRENCE AS CHIEF FINANCIAL OFFICER EXHIBIT 99.1 KORU MEDICAL SYSTEMS, INC. NAMES ANDREW LAFRENCE AS CHIEF FINANCIAL OFFICER MAHWAH, NJ – June 27, 2023 – KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty subcutaneous infusion solutions that improve quality of life fo
May 26, 2023	CORRESP	May 26, 2023 May 26, 2023 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549-3720 Attention: Conlon Danberg Re: Koru Medical Systems, Inc. Registration Statement on Form S-3 File No. 333-272026 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Koru Medical Systems, Inc. (the “Company”) hereby requests
May 26, 2023	S-3/A	As filed with the Securities and Exchange Commission on May 26, 2023 . As filed with the Securities and Exchange Commission on May 26, 2023 . Registration No. 333-272026 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Pre-Effective Amendment No. 1 to FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 KORU MEDICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorpor
May 18, 2023	EX-4	Form of Subordinated Indenture Exhibit 4.3 KORU MEDICAL SYSTEMS, INC. and Trustee INDENTURE Dated as of SUBORDINATED DEBT SECURITIES CROSS-REFERENCE TABLE 1 Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a) 4.02 31
May 18, 2023	EX-FILING FEES	Calculation of Filing Fee Tables EX-FILING FEES 8 ex107.htm CALCULATION OF FILING FEE TABLES Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) KORU Medical Systems, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maxim
May 18, 2023	S-8 POS	As filed with the Securities and Exchange Commission on May 17, 2023 As filed with the Securities and Exchange Commission on May 17, 2023 Registration No.
May 18, 2023	S-8 POS	As filed with the Securities and Exchange Commission on May 17, 2023 S-8 POS 1 forms-8.htm POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT As filed with the Securities and Exchange Commission on May 17, 2023 Registration No. 333-262054 Registration No. 333-265943 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-262054 Post-Effective Amendment No. 1 to
May 18, 2023	EX-4	Form of Senior Indenture Exhibit 4.2 KORU MEDICAL SYSTEMS, INC. and Trustee INDENTURE Dated as of SENIOR DEBT SECURITIES CROSS-REFERENCE TABLE1 Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a) 4.02 314(b) In
May 18, 2023	EX-4	Form of Subordinated Note Exhibit 4.5 Form of Subordinated Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE
May 18, 2023	S-3	Powers of Attorney As filed with the Securities and Exchange Commission on May 17, 2023. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 KORU MEDICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 13-3044880 (I.R.S
May 18, 2023	EX-4	Form of Senior Note Exhibit 4.4 Form of Senior Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE OF THE
May 17, 2023	EX-3	Bylaws dated May 11, 2023 Exhibit 3.2 BY-LAWS OF KORU MEDICAL SYSTEMS, INC. ARTICLE I OFFICES Section 1.01 Registered Office. The registered office of Koru Medical Systems, Inc. (the “Corporation”) will be fixed in the Certificate of Incorporation of the Corporation (the “Certificate of Incorporation”). Section 1.02 Other Offices. The Corporation may have other offices, either within or without the State of Delaware, as th
May 17, 2023	EX-3	Certificate of Incorporation effective May 11, 2023 Exhibit 3.1 CERTIFICATE OF INCORPORATION OF KORU MEDICAL SYSTEMS, INC. ARTICLE I NAME OF THE CORPORATION The name of the corporation is Koru Medical Systems, Inc. (the “Corporation”). ARTICLE II REGISTERED AGENT The address of the registered office of the Corporation in the State of Delaware is 1675 South State Street, Suite B, Dover, Kent County, Delaware, 19901. The name of the registered agent
May 17, 2023	8-A12B/A	Description of Registrant’s Securities registered pursuant to Section 12 of the Securities Exchange Act of 1934 8-A12B/A 1 form8-a.htm FORM 8-A12B/A AMENDMENT TO REGISTRATION PURSUANT TO SECTION 12(B) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 KORU MEDICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 13-3044880 (State or other j
May 17, 2023	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Financial Statements and Exhibits, Other Events, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 16, 2023 KORU Medical Systems, Inc.
May 17, 2023	EX-2	Agreement and Plan of Merger by and between KORU Medical Systems, Inc., a New York corporation, and KORU Medical Systems, Inc., a Delaware corporation Exhibit 2.1 AGREEMENT AND PLAN OF MERGER This AGREEMENT AND PLAN OF MERGER (this “Merger Agreement”) is made and entered into as of the 12th day of May, 2023, by and between Koru Medical Systems, Inc., a New York corporation (“KORU (NY)”), and Koru Medical Systems, Inc., a Delaware corporation (“KORU (DE)”). BACKGROUND WHEREAS, the Board of Directors of KORU (NY) and the Board of Directors of KORU
May 4, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2023 or [] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 0-12305 KORU M
May 4, 2023	EX-99	KORU MEDICAL SYSTEMS, INC. ANNOUNCES 2023 FIRST QUARTER FINANCIAL RESULTS strong start to 2023 with 18% revenue growth EXHIBIT 99.1 KORU MEDICAL SYSTEMS, INC. ANNOUNCES 2023 FIRST QUARTER FINANCIAL RESULTS strong start to 2023 with 18% revenue growth MAHWAH, NJ – May 4, 2023 – KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty infusion solutions tha
May 4, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 4, 2023 KORU Medical Systems, In UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 4, 2023 KORU Medical Systems, Inc.
March 29, 2023	DEF 14A	Our Definitive Proxy Statement on Schedule 14A, filed with the SEC on March 29, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
March 8, 2023	EX-10	Employment Agreement effective as of March 18, 2022 between KORU Medical Systems, Inc. and Brian Case EX-10 2 ex10-15.htm EMPLOYMENT AGREEMENT MARCH 18, 2022 - BRIAN CASE Exhibit 10.15 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this “Agreement”) effective as of March 18, 2022, is made by and between Repro Med Systems, Inc. d/b/a KORU Medical Systems, a New York corporation, having its principal place of business at 24 Carpenter Road, Chester, NY 10918 (the “Company”), and Brian Case, an indiv
March 8, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-12305 KORU MEDICAL SYSTEMS, INC.
March 8, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 8, 2023 KORU Medical Systems, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 8, 2023 KORU Medical Systems, Inc.
March 8, 2023	EX-99	KORU Medical Systems Announces 2022 Q4 AND full year Financial Results, Accelerating to 19% REVENUE GROWTH in 2022 EXHIBIT 99.1 KORU Medical Systems Announces 2022 Q4 AND full year Financial Results, Accelerating to 19% REVENUE GROWTH in 2022 MAHWAH, NJ – March 8, 2023 –KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use subcutaneous drug delivery systems
February 24, 2023	SC 13D/A	KRMD / KORU Medical Systems Inc / Horton Capital Partners, LLC - SCHEDULE 13D/A AMENDMENT NO. 9 FOR 02-24-2023 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 9) KORU Medical Systems, Inc. (Name of Issuer) Common Stock, Par Value $0.01 Per Share (Title of Class of Securities) 759910102 (CUSIP Number) JOSEPH M. MANKO, JR. HORTON CAPITAL PARTNERS, LLC 1717 Arch Street, Suite 3740 Philadelphia, PA 19103 (215) 399 540
February 14, 2023	SC 13G/A	KRMD / Repro Med Systems, Inc. / First Light Asset Management, LLC - AMENDMENT TO FORM SC 13G Passive Investment SC 13G/A 1 krmd-sc13ga123122.htm AMENDMENT TO FORM SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* (Amendment No. 2) KORU Medical Systems, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 759910102 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Sta
February 13, 2023	SC 13G/A	KRMD / Repro Med Systems, Inc. / Archon Capital Management LLC Passive Investment SC 13G/A 1 d993139413g-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* KORU Medical Systems, Inc. (Name of Issuer) Common Stock, $0.01 Par Value (Title of Class of Securities) 759910102 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate b
November 9, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2022 or [] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 0-12305 KO
November 9, 2022	EX-99	KORU Medical Systems Announces 2022 Third Quarter Financial Results EXHIBIT 99.1 KORU Medical Systems Announces 2022 Third Quarter Financial Results MAHWAH, NJ ? November 9, 2022 ?KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use subcutaneous drug delivery systems that improve quality of life for patients, t
November 9, 2022	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 9, 2022 KORU Medical Systems, Inc.
August 3, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2022 or [] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 0-12305 KORU ME
August 3, 2022	EX-10	Amendment to Employment and Option Agreements dated as of August 2, 2022 between KORU Medical Systems, Inc. and Christopher Pazdan Exhibit 10.3 AMENDMENT TO EMPLOYMENT AND OPTION AGREEMENTS This AMENDMENT TO EMPLOYMENT AND OPTION AGREEMENTS (this ?Amendment?) is made and entered into as of August 2, 2022 (the ?Effective Date?), by and between KORU Medical Systems, Inc., a New York corporation (the ?Company?), and Christopher Pazdan ( ?Employee?). WHEREAS, the Company and Employee entered into that certain Employment Agreement
August 3, 2022	EX-10	Employment Agreement effective as of October 20, 2021 between KORU Medical Systems, Inc. and Thomas Adams Exhibit 10.1 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this ?Agreement?) effective as of October 20, 2021, is made by and between Repro Med Systems, Inc. d/b/a KORU Medical Systems, a New York corporation, having its principal place of business at 24 Carpenter Road, Chester, NY 10918 (the ?Company?), and Thomas Adams, an individual having a domicile at [address] (?Employee?). WHEREAS, the Co
August 3, 2022	EX-99	KORU Medical Systems Announces 2022 Second Quarter Financial Results EXHIBIT 99.1 KORU Medical Systems Announces 2022 Second Quarter Financial Results MAHWAH, NJ – August 3, 2022 –KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty infusion solutions that improve quality of life for patients, today re
August 3, 2022	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 3, 2022 KORU Medical Systems, Inc.
August 3, 2022	EX-10	Employment Agreement dated as of August 4, 2021 between KORU Medical Systems, Inc. and Christopher Pazdan Exhibit 10.2 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this ?Agreement?) effective as of August 4, 2021, is made by and between Repro Med Systems, Inc. d/b/a KORU Medical Systems, a New York corporation, having its principal place of business at 24 Carpenter Road, Chester, NY 10918 (the ?Company?), and Christopher Pazdan, an individual having a domicile at [address] (?Employee?). WHEREAS, th
July 6, 2022	8-K	Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 1, 2022 KORU Medical Systems, Inc.
July 6, 2022	EX-10	Pledge Agreement dated as of June 29, 2022 between the Company and KeyBank National Association Exhibit 10.2 PLEDGE SECURITY AGREEMENT * * * * * * * * * * THIS PLEDGE SECURITY AGREEMENT, dated as of June 29, 2022 (?this Agreement?), is made by REPRO MED SYSTEMS, INC., a New York corporation, whose principal place of business is located at 24 Carpenter Road, Chester, New York 10918-1057 (whether one or more, the ?Pledgor?), jointly and severally if more than one, and granted to KEYBANK NATION
July 6, 2022	EX-10	Loan Modification Extension Agreement dated June 29, 2022 between KORU Medical Systems, Inc. and KeyBank National Association Exhibit 10.1 LOAN MODIFICATION EXTENSION AGREEMENT * * * * * * * * * * THIS LOAN MODIFICATION EXTENSION AND ADDENDUM AGREEMENT (this ?Agreement?), made this 29th day of June, 2022 between REPRO MED SYSTEMS, INC., a New York corporation with an office at 24 Carpenter Road, Chester, New York 10918-1057 (the ?Borrower?), and KEYBANK NATIONAL ASSOCIATION, a national bank with an address of 170 S. High
June 30, 2022	S-8	As filed with the Securities and Exchange Commission on June 30, 2022 As filed with the Securities and Exchange Commission on June 30, 2022 Registration No.
June 30, 2022	EX-FILING FEES	Filing Fee Table EX-FILING FEES 4 ex107.htm CALCULATION OF FILING FEE TABLE Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) KORU Medical Systems, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1 — Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount to be Registered(1) Proposed Maximum Offering Price Per Share Proposed Maximum Aggregate Offe
June 28, 2022	EX-3	Certificate of Amendment to the Restated Certificate of Incorporation, as amended. Exhibit 3.1 CERTIFICATE OF AMENDMENT of the CERTIFICATE OF INCORPORATION of REPRO MED SYSTEMS, INC. Under Section 805 of the Business Corporation Law FIRST: The current name of the corporation is Repro Med Systems, Inc. SECOND: The date of filing of the certificate of incorporation with the Department of State is March 24, 1980. THIRD: The amendment effected by this certificate of amendment is as
June 28, 2022	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 22, 2022 KORU Medical Systems, Inc.
May 18, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 17, 2022 REPRO MED SYSTEMS, INC.
May 18, 2022	EX-10	Transition Agreement dated as of May 17, 2022 between Repro Med Systems, Inc. and Karen Fisher Exhibit 10.1 TRANSITION AGREEMENT THIS TRANSITION AGREEMENT (this ?Agreement?) effective as of May 17, 2022 (the ?Effective Date?), is made by and between Repro Med Systems, Inc. d/b/a KORU Medical Systems, a New York corporation, having its principal place of business at 24 Carpenter Road, Chester, NY 10918 (the ?Company?), and Karen Fisher (?Executive?). Reference is made to that certain Amended
May 10, 2022	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 6, 2022 REPRO MED SYSTEMS, INC.
May 4, 2022	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 4, 2022 REPRO MED SYSTEMS, INC.
May 4, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2022 or [] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 0-12305 REPRO
May 4, 2022	EX-99	KORU Medical Systems Announces 2022 First Quarter Financial Results EXHIBIT 99.1 KORU Medical Systems Announces 2022 First Quarter Financial Results CHESTER, NY ? May 4, 2022 ? Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty infusion solutions that improve quality of life fo
March 18, 2022	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) DEF 14A 1 schedule14a.htm SCHEDULE 14A DEFINITIVE PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential,
March 7, 2022	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [X] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
March 2, 2022	EX-10	Lease dated as of January 21, 2022 between the Company and Breit Industrial Canyon NJ1W05 LLC EX-10 3 ex10-16.htm LEASE DATED AS OF 01-21-2022 EXHIBIT 10.16 LEASE This Lease (this “Lease”) is made and entered into as of January 21st, 2022, by and between BREIT INDUSTRIAL CANYON NJ1W05 LLC, a Delaware limited liability company (“Landlord”), and REPRO MED SYSTEMS, INC., a New York corporation dba Koru Medical Systems (“Tenant”). 1. BASIC TERMS AND DEFINITIONS. (a) Definitions: The capitalize
March 2, 2022	EX-10	Lease Extension Agreement dated February 16, 2022 EXHIBIT 10.3 Lease Extension Agreement THIS LEASE EXTENSION AGREEMENT dated the 16th day of February , 2022 by and between CASPER CREEK, LLC, a New York limited liability company, with an address at c/o Eagle-Riverview Group Inc., 1 Civic Center Plaza, Suite 500, Poughkeepsie, New York 12601 (the ?Landlord?) and REPRO MED SYSTEMS, INC. d/b/a KORU MEDICAL SYSTEMS, (the ?Tenant?) regarding the premi
March 2, 2022	EX-99	KORU MEDICAL SYSTEMS ANNOUNCES 2021 Q4 AND FULL YEAR FINANCIAL RESULTS EX-99 2 ex99-1.htm PRESS RELEASE DATED MARCH 2, 2022 EXHIBIT 99.1 KORU MEDICAL SYSTEMS ANNOUNCES 2021 Q4 AND FULL YEAR FINANCIAL RESULTS CHESTER, NY – March 2, 2022 – Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use sp
March 2, 2022	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 2, 2022 REPRO MED SYSTEMS, INC.
March 2, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-12305 REPRO MED SYSTEMS, INC.
February 14, 2022	SC 13G/A	KRMD / Repro Med Systems, Inc. / First Light Asset Management, LLC - AMENDMENT TO FORM SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* (Amendment No. 2) Repro Med Systems, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 759910102 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu
February 14, 2022	SC 13G	KRMD / Repro Med Systems, Inc. / Archon Capital Management LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
January 7, 2022	S-8	As filed with the Securities and Exchange Commission on January 7, 2022 As filed with the Securities and Exchange Commission on January 7, 2022 Registration No.
December 10, 2021	8-K	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 9, 2021 REPRO MED SYSTEMS, INC.
December 7, 2021	EX-99	KORU Medical Systems to Unveil Updated Strategic Plan at Investor Day EXHIBIT 99.1 KORU Medical Systems to Unveil Updated Strategic Plan at Investor Day December 01, 2021 04:01 PM Eastern Standard Time CHESTER, N.Y.-(BUSINESS WIRE)-Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) (?KORU Medical? or the ?Company?), a leading medical technology company focused on the development of innovative and easy-to-use home infusion solutions, today announced it w
December 7, 2021	8-K	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 1, 2021 REPRO MED SYSTEMS, INC.
November 10, 2021	EX-99	KORU MEDICAL SYSTEMS ANNOUNCES 2021 THIRD QUARTER FINANCIAL RESULTS EX-99 2 ex99-1.htm PRESS RELEASE DATED NOVEMBER 10, 2021 EXHIBIT 99.1 KORU MEDICAL SYSTEMS ANNOUNCES 2021 THIRD QUARTER FINANCIAL RESULTS CHESTER, NY – November 10, 2021 – Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-u
November 10, 2021	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 10, 2021 REPRO MED SYSTEMS, INC.
November 10, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2021 or [] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 0-12305 RE
August 11, 2021	EX-99	KORU Medical Systems Announces 2021 Second Quarter Financial Results EXHIBIT 99.1 KORU Medical Systems Announces 2021 Second Quarter Financial Results CHESTER, NY ? August 11, 2021 ? Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty infusion solutions that improve quality of li
August 11, 2021	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 11, 2021 REPRO MED SYSTEMS, INC.
August 11, 2021	EX-10	Summary of Non-Employee Director Compensation (effective May 18, 2021) EX-10 2 ex10-1.htm SUMMARY OF NON-EMPLOYEE DIRECTOR COMPENSATION EXHIBIT 10.1 Repro Med Systems, Inc. d/b/a KORU Medical Systems Summary of Non-Employee Director Compensation The Board of Directors of Repro Med Systems, Inc. d/b/a KORU Medical Systems (the “Company”) has approved the following compensation for its non-employee directors effective with approval of the Company’s 2021 Omnibus Equity
August 11, 2021	EX-10	Form of non-qualified/incentive stock option award agreement pursuant to the 2021 Omnibus Equity Inventive Plan EX-10 4 ex10-3.htm FORM OF NON-QUALIFIED/INCENTIVE STOCK OPTION AWARD AGREEMENT EXHIBIT 10.3 NONQUALIFIED STOCK OPTION AGREEMENT UNDER THE REPRO MED SYSTEMS, INC. 2021 OMNIBUS EQUITY INCENTIVE PLAN Name of Grantee: (the “Grantee”) No. of Shares Underlying Options: (the “Underlying Shares”) Grant Date: (the “Grant Date”) Vesting Commencement Date: (“Vesting Commencement Date”) Expiration Date: (the
August 11, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2021 or [] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 0-12305 REPRO M
August 11, 2021	EX-10	Repro Med Systems, Inc. 2021 Omnibus Equity Incentive Plan EX-10 3 ex10-2.htm REPRO MED SYSTEMS, INC. 2021 OMNIBUS EQUITY INCENTIVE PLAN EXHIBIT 10.2 FOR APPROVAL BY BOARD REPRO MED SYSTEMS, INC. 2021 OMNIBUS EQUITY INCENTIVE PLAN TABLE OF CONTENTS Article 1. Effective Date, Objectives and Duration 3 Article 2. Definitions 3 Article 3. Administration 7 Article 4. Shares Subject to the Plan 10 Article 5. Eligibility and General Conditions of Awards 12 Arti
August 11, 2021	EX-10	Form of Indemnification Agreement between Repro Med Systems, Inc. and each of its directors and executive officers EXHIBIT 10.4 INDEMNIFICATION AGREEMENT This Indemnification Agreement (this ?Agreement?) is made as of , 2021 by and between Repro Med Systems, Inc. d/b/a KORU Medical Systems, a New York corporation (the ?Company?), and (?Indemnitee?). WHEREAS, highly competent persons have become more reluctant to serve publicly-held corporations as directors or officers or in other capacities unless they are pr
May 19, 2021	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 18, 2021 REPRO MED SYSTEMS, INC.
May 12, 2021	EX-99	KORU MEDICAL SYSTEMS ANNOUNCES 2021 FIRST QUARTER FINANCIAL RESULTS EX-99 2 ex99-1.htm PRESS RELEASE DATED MAY 12, 2021 EXHIBIT 99.1 KORU MEDICAL SYSTEMS ANNOUNCES 2021 FIRST QUARTER FINANCIAL RESULTS CHESTER, NY – May 12, 2021 – Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use special
May 12, 2021	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 12, 2021 REPRO MED SYSTEMS, INC.
May 12, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2021 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 0-12305 REPRO
April 6, 2021	SC 13D/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 8) REPRO MED SYSTEMS, INC. (Name of Issuer) Common Stock, Par Value $0.01 Per Share (Title of Class of Secur UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 8) REPRO MED SYSTEMS, INC. (Name of Issuer) Common Stock, Par Value $0.01 Per Share (Title of Class of Securities) 759910102 (CUSIP Number) JOSEPH M. MANKO, JR. HORTON CAPITAL PARTNERS, LLC 1717 Arch Street, Suite 3920 Philadelphia, PA 19103 (215) 399 5402 (
April 5, 2021	DEF 14A	2021 Omnibus Equity Incentive Plan UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
March 23, 2021	EX-10	Form of Non-Qualified Stock Option EXHIBIT 10.5 REPRO MED SYSTEMS, INC. 2015 STOCK OPTION PLAN NONQUALIFIED STOCK OPTION AWARD This NONQUALIFIED STOCK OPTION AWARD (this ?Agreement?), dated as of , (the ?Date of Grant?), is delivered by Repro Med Systems, Inc., a New York corporation (the ?Company?), to (the ?Grantee?). The Company?s 2015 Stock Option Plan (the ?Plan?) provides for the grant of nonqualified stock options to purchas
March 23, 2021	10-K	Annual Report - FORM 10-K ANNUAL REPORT FOR 12-31-2020 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 0-12305 REPRO MED SYSTEMS, INC.
March 23, 2021	EX-4	Description of Securities EX-4 2 ex4-1.htm DESCRIPTION OF SECURITIES EXHIBIT 4.1 Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 The following discussion summarizes the terms and provisions of the capital stock of Repro Med Systems, Inc. (the “Company” or “we” or “our”). This description is summarized from, and qualified in its entirety by reference to, ou
March 23, 2021	PRE 14A	- SCHEDULE 14A PRELIMINARY PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [X] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
March 23, 2021	EX-10	Form of Incentive Stock Option EXHIBIT 10.6 INCENTIVE STOCK OPTION AGREEMENT This INCENTIVE STOCK OPTION AGREEMENT (?Agreement?), dated as of , (the ?Date of Grant?), is by and between Repro Med Systems, Inc., a New York corporation (the ?Company?), and (the ?Employee?), residing at . WHEREAS, the Company has duly adopted, and its shareholders approved, the 2015 Stock Option Plan of Repro Med Systems, Inc. (as amended, the ?Pla
March 23, 2021	EX-99	KORU Medical Systems Reports Fourth Quarter and Full Year 2020 Financial Results Exhibit 99.1 KORU Medical Systems Reports Fourth Quarter and Full Year 2020 Financial Results CHESTER, NY ? March 23, 2021 ? Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) (?KORU Medical? or the ?Company?) a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty infusion solutions that improve qua
March 23, 2021	EX-10	Employment Agreement effective as of March 15, 2021 between KORU Medical Systems, Inc. and Linda Tharby EX-10 6 ex10-15.htm EMPLOYMENT AGREEMENT MARCH 15, 2021 - LINDA THARBY EXHIBIT 10.15 CERTAIN INFORMATION, IDENTIFIED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD CAUSE COMPETITIVE HARM IF DISCLOSED. EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this “Agreement”), dated as of March 15, 2021 (the “Effective Date”), is made by and between Repro Med Systems, Inc. d/b/a KORU Medica
March 23, 2021	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 23, 2021 REPRO MED SYSTEMS, INC.
March 23, 2021	EX-10	Separation Agreement and General Release dated January 24, 2021 between the Company and Donald B. Pettigrew EXHIBIT 10.9 SEPARATION AND GENERAL RELEASE AGREEMENT This SEPARATION AND GENERAL RELEASE AGREEMENT (this ?Agreement?) is made and entered into by and between Donald B. Pettigrew (?Executive?) and Repro Med Systems, Inc., a New York corporation (the ?Company?). Executive and the Company are referred to herein, collectively, as the ?Parties,? and each, a ?Party.? WHEREAS, Executive was employed by
March 19, 2021	EX-99	KORU Medical Systems Announces New Chief Executive Officer Exhibit 99.1 KORU Medical Systems Announces New Chief Executive Officer CHESTER, NY ? March 19, 2021 ? Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) (?KORU Medical? or the ?Company?), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty infusion solutions that help improve quality of life for
March 19, 2021	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 15, 2021 REPRO MED SYSTEMS, INC.
February 11, 2021	8-K	- FORM 8-K CURRENT REPORT FOR 02-05-2021 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 5, 2021 REPRO MED SYSTEMS, INC.
February 11, 2021	EX-10	Employment Agreement dated as of January 22, 2021 between Repro Med Systems, Inc. and James M. Beck EX-10 2 ex10-1.htm EMPLOYMENT AGREEMENT DATED AS OF 01-22-2021 - JAMES M. BECK Exhibit 10.1 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this “Agreement”) is made as of January 22, 2021 (the “Effective Date”) by and between Repro Med Systems, Inc., a New York corporation, having its principal place of business at 24 Carpenter Road, Chester NY (the “Company”), and James M. Beck (“Executive”). WH
January 26, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Results of Operations and Financial Condition - FORM 8-K CURRENT REPORT FOR 01-22-2021 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 22, 2021 REPRO MED SYSTEMS, INC.
January 26, 2021	EX-99	KORU Medical Systems Reports Preliminary Full Year 2020 Results; Announces CEO Transition EX-99 2 ex99-1.htm PRESS RELEASE DATED JANUARY 25, 2021 Exhibit 99.1 KORU Medical Systems Reports Preliminary Full Year 2020 Results; Announces CEO Transition CHESTER, NY – January 25, 2021 – Repro Med Systems, Inc. dba KORU Medical Systems NASDAQ: KRMD) (“KORU Medical” or the “Company”) a leading medical technology company focused on the development, manufacturing, and commercialization of innova
January 8, 2021	SC 13G/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* (Amendment No. 2) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* (Amendment No. 2) Repro Med Systems, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 759910102 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu
November 17, 2020	8-K	Regulation FD Disclosure - FORM 8-K CURRENT REPORT FOR 11-17-2020 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 17, 2020 REPRO MED SYSTEMS, INC.
November 17, 2020	EX-99	Exhibit 99.1 Exhibit 99.1
November 17, 2020	EX-99	KORU MEDICAL SYSTEMS ANNOUNCES STOCK REPURCHASE PROGRAM Exhibit 99.1 FOR IMMEDIATE RELEASE KORU MEDICAL SYSTEMS ANNOUNCES STOCK REPURCHASE PROGRAM CHESTER, NY ? November 16, 2020 ? Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) (?KORU Medical? or the ?Company?) today announced that its Board of Directors has authorized a stock repurchase program under which the Company may purchase up to $10 million of its outstanding common stock thro
November 17, 2020	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 16, 2020 REPRO MED SYSTEMS, INC.
November 12, 2020	10-Q	Quarterly Report - FORM 10-Q QUARTERLY REPORT FOR 09-30-2020 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2020 Or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 0-12305 R
November 12, 2020	EX-10	Manufacturing and Supply Agreement dated as of November 11, 2020 between KORU Medical Systems, Inc. and Command Medical Products EX-10 2 ex10-1.htm MANUFACTURING AND SUPPLY AGREEMENT - COMMAND MEDICAL PRODUCTS Exhibit 10.1 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED, AND THE EXCLUDED TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH THREE ASTERISKS [***]. MANUFACTURING AND SUPPLY AGREEMENT This Manufact
November 4, 2020	EX-99	KORU MEDICAL SYSTEMS ANNOUNCES FINANCIAL RESULTS FOR THIRD QUARTER 2020 Exhibit 99.1 FOR IMMEDIATE RELEASE KORU MEDICAL SYSTEMS ANNOUNCES FINANCIAL RESULTS FOR THIRD QUARTER 2020 CHESTER, NY – November 3, 2020 – Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”) today announced financial results for the third quarter ended September 30, 2020 (“Q3 2020”). Q3 2020 Overview “The strength and resiliency of our core business,
November 4, 2020	8-K	Results of Operations and Financial Condition - FORM 8-K CURRENT REPORT FOR 11-03-2020 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 3, 2020 REPRO MED SYSTEMS, INC.
August 20, 2020	SC 13D/A	KRMD / Repro Med Systems, Inc. / Horton Capital Partners, LLC - SC 13D/A Activist Investment SC 13D/A 1 d207975dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 7) REPRO MED SYSTEMS, INC. (Name of Issuer) Common Stock, Par Value $0.01 Per Share (Title of Class of Securities) 759910102 (CUSIP Number) JOSEPH M. MANKO, JR. HORTON CAPITAL PARTNERS, LLC 1717 Arch Street, Suite 3920
August 20, 2020	EX-99.1	JOINT FILING AGREEMENT EX-99.1 2 d207975dex991.htm EXHIBIT 1 Exhibit 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing with the Securities and Exchange Commission on behalf of each of them of Schedule 13D/A, to which this Exhibit 1 is attached (including amendments thereto) with respect to certain shares
August 5, 2020	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 4, 2020 REPRO MED SYSTEMS, INC.
August 5, 2020	EX-99	KORU MEDICAL SYSTEMS ANNOUNCES 2020 SECOND QUARTER FINANCIAL RESULTS Record Net Sales of $7.7 Million, Gross Margin of 64% EX-99 2 ex99-1.htm PRESS RELEASE DATED AUGUST 4, 2020 Exhibit 99.1 FOR IMMEDIATE RELEASE KORU MEDICAL SYSTEMS ANNOUNCES 2020 SECOND QUARTER FINANCIAL RESULTS Record Net Sales of $7.7 Million, Gross Margin of 64% CHESTER, NY – August 4, 2020 – Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”) today announced financial results for the second quarter en
August 5, 2020	10-Q	Quarterly Report - FORM 10-Q QUARTERLY REPORT FOR 06-30-2020 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2020 Or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 0-12305 REPRO
June 22, 2020	EX-99	KORU Medical Prices Public Offering of Common Stock EX-99 5 ex99-2.htm PRESS RELEASE ANNOUNCING PRICING OF OFFERING DATED JUNE 19, 2020 Exhibit 99.2 KORU Medical Prices Public Offering of Common Stock CHESTER, NY, June 19, 2020 – BUSINESS WIRE - Repro Med Systems, Inc. d/b/a KORU Medical Systems (Nasdaq: KRMD) (“KORU Medical”) today announced the pricing of its previously announced underwritten public offering of 3,125,000 shares of its common stoc
June 22, 2020	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 18, 2020 REPRO MED SYSTEMS, INC.
June 22, 2020	424B5	Per Share 424B5 1 prospectus424b5.htm PROSPECTUS SUPPLEMENT TO PROSPECTUS DATED 05-20-2020 Filed Pursuant to Rule 424(b)(5) Registration No. 333-238242 PROSPECTUS SUPPLEMENT To Prospectus dated May 20, 2020 REPRO MED SYSTEMS, INC. 3,125,000 Shares Common Stock We are offering 3,125,000 shares of our common stock. Our common stock is listed on the Nasdaq Capital Market under the symbol “KRMD.” On June 17, 20
June 22, 2020	EX-1	Purchase Agreement, dated June 18, 2020 by and among Repro Med Systems, Inc. Piper Sandler & Co. and Canaccord Genuity LLC, as representatives of the several underwriters named therein EX-1 2 ex1-1.htm PURCHASE AGREEMENT DATED JUNE 18, 2020 Exhibit 1.1 3,125,000 Shares Repro Med Systems, Inc. Common Stock PURCHASE AGREEMENT June 18, 2020 PIPER SANDLER & CO. CANACCORD GENUITY LLC As Representatives of the several Underwriters named in Schedule I hereto c/o Piper Sandler & Co. U.S. Bancorp Center 800 Nicollet Mall Minneapolis, Minnesota 55402 c/o Canaccord Genuity LLC 99 High Stre
June 22, 2020	EX-99	KORU Medical Commences Public Offering of Common Stock EX-99 4 ex99-1.htm PRESS RELEASE ANNOUNCING COMMENCEMENT OF OFFERING DATED JUNE 18, 2020 Exhibit 99.1 KORU Medical Commences Public Offering of Common Stock CHESTER, NY, June 18, 2020 – BUSINESS WIRE - Repro Med Systems, Inc. d/b/a KORU Medical Systems (Nasdaq: KRMD) (“KORU Medical”) today announced that it has commenced an underwritten public offering of the sale of its shares of common stock. In
June 18, 2020	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 18, 2020 REPRO MED SYSTEMS, INC.
June 18, 2020	EX-99	Exhibit 99.1 Exhibit 99.1
June 18, 2020	424B5	SUBJECT TO COMPLETION, DATED JUNE 18, 2020 Filed Pursuant to Rule 424(b)(5) Registration No. 333-238242 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are part of an effective registration statement filed with the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanying prospectus are
May 26, 2020	8-K	Financial Statements and Exhibits, Other Events 8-K 1 form8-k.htm FORM 8-K CURRENT REPORT FOR 05-20-2020 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 20, 2020 REPRO MED SYSTEMS, INC. (Exact name of registrant as specified in its charter) New York 0-12305 13-3044880 (State or
May 26, 2020	EX-99	KORU MEDICAL SYSTEMS AND EMED TECHNOLOGIES CORPORATION ANNOUNCE SETTLEMENT OF ALL PENDING LITIGATION Exhibit 99.1 FOR IMMEDIATE RELEASE KORU MEDICAL SYSTEMS AND EMED TECHNOLOGIES CORPORATION ANNOUNCE SETTLEMENT OF ALL PENDING LITIGATION CHESTER, NY – May 26, 2020 – Repro Med Systems, Inc. d/b/a KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical”) and EMED Technologies Corporation (“EMED”) today announced the settlement of all ongoing litigation between the two companies, including patent, antitru
May 18, 2020	CORRESP	- May 18, 2020 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549-3720 Attention: Paul Fischer Re: Repro Med Systems, Inc. Registration Statement on Form S-3 File No. 333-238242 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Repro Med Systems, Inc. (the “Company”) hereby requests that the
May 14, 2020	EX-4	Form of Subordinated Note EX-4 5 ex4-7.htm FORM OF SUBORDINATED NOTE Exhibit 4.7 Form of Subordinated Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOS
May 14, 2020	S-3	- FORM S-3 REGISTRATION STATEMENT As filed with the Securities and Exchange Commission on May 14, 2020. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 REPRO MED SYSTEMS, INC. (Exact name of registrant as specified in its charter) New York (State or other jurisdiction of incorporation or organization) 13-3044880 (I.R.S. E
May 14, 2020	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 13, 2020 REPRO MED SYSTEMS, INC.
May 14, 2020	EX-4	Form of Subordinated Indenture Exhibit 4.5 REPRO MED SYSTEMS, INC. and Trustee INDENTURE Dated as of SUBORDINATED DEBT SECURITIES CROSS-REFERENCE TABLE 1 Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a) 4.02 314(b
May 14, 2020	EX-4	Form of Senior Indenture EX-4 2 ex4-4.htm FORM OF SENIOR INDENTURE Exhibit 4.4 REPRO MED SYSTEMS, INC. and Trustee INDENTURE Dated as of SENIOR DEBT SECURITIES CROSS-REFERENCE TABLE1 Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c)
May 14, 2020	EX-4	Form of Senior Note EX-4 4 ex4-6.htm FORM OF SENIOR NOTE Exhibit 4.6 Form of Senior Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE
May 7, 2020	EX-99	POWER OF ATTORNEY EXHIBIT 99.1 TO FORM 3 POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints each of Donald Pettigrew and Karen Fisher and their successors in office and designees, signing singly, the undersigned’s true and lawful attorney-in-fact to: (1) execute and file for and on behalf of the undersigned, in the undersigned’s capacity as an officer and/or director
May 6, 2020	10-Q	Quarterly Report - FORM 10-Q QUARTERLY REPORT FOR 03-31-2020 10-Q 1 form10-q.htm FORM 10-Q QUARTERLY REPORT FOR 03-31-2020 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2020 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the tra
May 5, 2020	EX-99	KORU MEDICAL SYSTEMS ANNOUNCES 2020 FIRST QUARTER FINANCIAL RESULTS Exhibit 99.1 KORU MEDICAL SYSTEMS ANNOUNCES 2020 FIRST QUARTER FINANCIAL RESULTS Q1 2020 Summary • Net sales rose 27% to $6.3 million • Gross margin of 60% (62% excluding inventory obsolescence charge) • Net income improved to $0.4 million, or $0.01 per share • Adjusted EBITDA increased 38% to $1.3 million • COVID-19 Update CHESTER, NY – May 4, 2020 – Repro Med Systems, Inc. dba KORU Medical Syste
May 5, 2020	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 4, 2020 REPRO MED SYSTEMS, INC.
April 30, 2020	EX-10	Master Security Agreement dated as of April 20, 2020 between the Company and Key Equipment Finance, a Division of KeyBank National Association EX-10 6 ex10-5.htm MASTER SECURITY AGREEMENT DATED 04-20-2020 - KEY EQUIPMENT FINANCE Exhibit 10.5 Master Security Agreement THIS MASTER SECURITY AGREEMENT (this “Agreement”) dated as of April 20, 2020 is made by and between REPRO MED SYSTEMS, INC., a New York Corporation, with a principal address at 24 CARPENTER RD, CHESTER, NY 10918-1057 (“Borrower”), and KEY EQUIPMENT FINANCE, A DIVISION OF KEY
April 30, 2020	EX-10	Promissory Note in the aggregate principal amount of $3.5 million dated April 14, 2020 issued by the Company to KeyBank National Association EX-10 2 ex10-1.htm PROMISSORY NOTE $3.5M DATED 04-14-2020 - KEYBANK NATIONAL Exhibit 10.1 PROMISSORY NOTE Principal $3,500,000.00 Loan Date 04-14-2020 Maturity 06-01-2021 Loan No Call / Coll Account Officer Initials References in the boxes above are for the Lender’s use only and do not limit the applicability of this document to any particular loan or item. Any item above containing “***” has been
April 30, 2020	EX-10	Loan Agreement dated April 20, 2020 between the Company and KeyBank National Association EX-10 4 ex10-3.htm LOAN AGREEMENT DATED 04-20-2020 - KEYBANK NATIONAL Exhibit 10.3 LOAN AGREEMENT * * * * * * * * * * THIS LOAN AGREEMENT (“Agreement”) is made on April 20, 2020, between the REPRO MED SYSTEMS, INC. and KEYBANK NATIONAL ASSOCIATION identified in the SBA Approval issued by the U.S. Small Business Administration (“SBA”) to Lender, dated April 12, 2020 SBA Loan Number 40340571-03 (“Ap
April 30, 2020	EX-10	Commercial Security Agreement dated April 14, 2020 between the Company and KeyBank National Association EX-10 3 ex10-2.htm COMMERCIAL SECURITY AGREEMENT DATED 04-14-2020 - KEYBANK NATIONAL Exhibit 10.2 COMMERCIAL SECURITY AGREEMENT Principal $3,500,000.00 Loan Date 04-14-2020 Maturity 06-01-2021 Loan No Call / Coll Account Officer Initials References in the boxes above are for the Lender’s use only and do not limit the applicability of this document to any particular loan or item. Any item above con
April 30, 2020	8-K	Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 8-K 1 form8-k.htm FORM 8-K CURRENT REPORT FOR 03-23-2020 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 23, 2020 REPRO MED SYSTEMS, INC. (Exact name of registrant as specified in its charter) New York 0-12305 13-3044880 (State
April 30, 2020	EX-10	Progress Payment Loan and Security Agreement dated as of April 20, 2020 between the Company and Key Equipment Finance, a Division of KeyBank National Association EX-10 5 ex10-4.htm PROGRESS PAYMENT LOAN & SECURITY AGREEMENT DATED 04-20-2020 - KEY EQUIPMENT FINANCE Exhibit 10.4 Progress Payment Loan and Security Agreement Principal Amount: $2,500,000.00 Interest Rate: Prime + 0.00% THIS PROGRESS PAYMENT LOAN AND SECURITY AGREEMENT dated as of April 20, 2020 (“Agreement”) is made by and between KEY EQUIPMENT FINANCE, A DIVISION OF KEYBANK NATIONAL ASSOCIATIO
April 24, 2020	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 22, 2020 REPRO MED SYSTEMS, INC.
April 14, 2020	EX-10	Management Incentive Compensation Plan Exhibit 10.1 REPRO MED SYSTEMS, INC. d/b/a KORU MEDICAL SYSTEMS MANAGEMENT INCENTIVE COMPENSATION PLAN 1. Purpose. The Management Incentive Compensation Plan (the “MICP”) has been established by Repro Med Systems, Inc. (the “Company”) for the purposes of (a) reinforcing the link between compensation and performance, (b) motivating participants to achieve individual and/or corporate performance obj
April 14, 2020	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 13, 2020 REPRO MED SYSTEMS, INC.
April 14, 2020	EX-99	UNITED STATES FEDERAL COURT OF APPEALS RULES IN FAVOR OF KORU MEDICAL SYSTEMS Exhibit 99.1 FOR IMMEDIATE RELEASE UNITED STATES FEDERAL COURT OF APPEALS RULES IN FAVOR OF KORU MEDICAL SYSTEMS CHESTER, NY – April 13, 2020 - Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”) today announced that on April 9, 2020 The United States Court of Appeals for the Federal Circuit (“the Federal Circuit Court”) affirmed an earlier decision by
March 31, 2020	DEFA14A	KRMD / Repro Med Systems, Inc. DEFA14A - - SCHEDULE 14A ADDITIONAL DEFINITIVE MATERIALS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
March 12, 2020	424B3	REPRO MED SYSTEMS, INC. 10,001,697 shares of common stock 424B3 1 prospectus424b3.htm PROSPECTUS 424(B)(3) Filed pursuant to Rule 424(b)(3) PROSPECTUS Registration No. 333-229498 REPRO MED SYSTEMS, INC. 10,001,697 shares of common stock This prospectus relates to the sale by the selling shareholders identified in this prospectus, or their assigns of up to an aggregate of 10,001,697 shares of our common stock (the “Shares”). We are registering the offer a
March 6, 2020	DEF 14A	KRMD / Repro Med Systems, Inc. DEF 14A - - SCHEDULE 14A DEFINITIVE PROXY STATEMENT DEF 14A 1 schedule14a.htm SCHEDULE 14A DEFINITIVE PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential,
March 4, 2020	EX-10	Employment Agreement made as of October 10, 2017 between Repro Med Systems, Inc. and Manuel Marques EX-10 3 ex10-3.htm EMPLOYMENT AGREEMENT AS OF 10-10-2017 - MANUEL MARQUES EXHIBIT 10.3 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this “Agreement”), made effective as of October 10, 2017 (the “Effective Date”), is made by and among Repro Med Systems, Inc., a New York corporation, having its principal place of business at 24 Carpenter Road, Chester, NY 10918 (the “Company”), and Manuel Marques
March 4, 2020	POS AM	KRMD / Repro Med Systems, Inc. POS AM - - POST EFFECTIVE AMENDMENT NO. 1 TO FORM S-1 ON FORM S-3 REGISTRATION STATEMENT As filed with the Securities and Exchange Commission on March 4, 2020 Registration No.
March 4, 2020	EX-4	Description of Securities EXHIBIT 4.1 DESCRIPTION OF CAPITAL STOCK Repro Med Systems, Inc. (“we” or “our”) has authorized capital stock consisting of 77,000,000 shares, of which 75,000,000 are designated common stock, $0.01 par value per share, and 2,000,000 are designated preferred stock. As of March 3, 2020, we had 39,502,557 shares of common stock and no shares of preferred stock issued and outstanding. Unless stated ot
March 4, 2020	10-K	KRMD / Repro Med Systems, Inc. 10-K - Annual Report - FORM 10-K ANNUAL REPORT FOR 12-31-2019 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 0-12305 REPRO MED SYSTEMS, INC.
February 25, 2020	424B3	PROSPECTUS SUPPLEMENT NO. 15 (to Prospectus dated March 8, 2019) REPRO MED SYSTEMS, INC. 11,101,697 shares of common stock 424B3 1 prospectus424b3-sup15.htm PROSPECTUS SUPPLEMENT NO. 15 TO 424(B)(3) Filed Pursuant to Rule 424(b)(3) Registration No. 333-229498 PROSPECTUS SUPPLEMENT NO. 15 (to Prospectus dated March 8, 2019) REPRO MED SYSTEMS, INC. 11,101,697 shares of common stock This prospectus supplement No. 15 supplements and amends the prospectus dated March 8, 2019, as supplemented by prospectus supplement No. 1,
February 25, 2020	EX-99	KORU Medical Systems Announces Record 2019 Fourth Quarter and Full Year Financial Results Conference Call Scheduled for February 26 at 9:00 am ET Exhibit 99.1 KORU Medical Systems Announces Record 2019 Fourth Quarter and Full Year Financial Results Conference Call Scheduled for February 26 at 9:00 am ET Q4 2019 Highlights • Net sales rose 45.7% to $6.2 million • Gross margin of 63.4% • Net loss narrowed to $0.1 million • Adjusted EBITDA increased 47.3% to $1.1 million Full Year 2019 Highlights • Net sales rose 33.5% to a record $23.2 millio
February 25, 2020	8-K	Results of Operations and Financial Condition 8-K 1 form8-k.htm FORM 8-K CURRENT REPORT FOR 02-25-2020 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 25, 2020 REPRO MED SYSTEMS, INC. (Exact name of registrant as specified in its charter) New York 0-12305 13-3044880 (Sta
February 14, 2020	SC 13G/A	REPR / Repro Med Systems, Inc. / First Light Asset Management, LLC - AMENDMENT TO FORM SC 13G Passive Investment SC 13G/A 1 repr-sc13ga123119.htm AMENDMENT TO FORM SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* (Amendment No. 2) Repro Med Systems, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 759910102 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statem
January 29, 2020	SC 13D/A	REPR / Repro Med Systems, Inc. / Horton Capital Partners, LLC - SCHEDULE 13D/A AMENDMENT NO. 6 FOR 08-07-2019 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 6) REPRO MED SYSTEMS, INC. (Name of Issuer) Common Stock, Par Value $0.01 Per Share (Title of Class of Securities) 759910102 (CUSIP Number) JOSEPH M. MANKO, JR. HORTON CAPITAL MANAGEMENT, LLC 1717 Arch Street, Suite 3920 Philadelphia, PA 19103 (215) 399 5402
January 24, 2020	EX-10	Amended and Restated Employment Agreement made as of January 1, 2020 between Repro Med Systems, Inc. and Karen Fisher EX-10 2 ex10-1.htm EMPLOYMENT AGREEMENT DATED 01-01-2020 - KAREN FISHER Exhibit 10.1 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”) is made as of January 1, 2020 (the “Effective Date”) by and between Repro Med Systems, Inc., a New York corporation, having its current principal place of business at 24 Carpenter Road, Chester, NY 10918 (th
January 24, 2020	8-K	Current Report 8-K 1 form8-k.htm FORM 8-K CURRENT REPORT FOR 01-23-2020 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 23, 2020 REPRO MED SYSTEMS, INC. (Exact name of registrant as specified in its charter) New York 0-12305 13-3044880 (Stat
January 24, 2020	424B3	PROSPECTUS SUPPLEMENT NO. 14 (to Prospectus dated March 8, 2019) REPRO MED SYSTEMS, INC. 11,101,697 shares of common stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-229498 PROSPECTUS SUPPLEMENT NO. 14 (to Prospectus dated March 8, 2019) REPRO MED SYSTEMS, INC. 11,101,697 shares of common stock This prospectus supplement No. 14 supplements and amends the prospectus dated March 8, 2019, as supplemented by prospectus supplement No. 1, dated April 29, 2019, as further supplemented by prospectus supplement No.
November 14, 2019	424B3	PROSPECTUS SUPPLEMENT NO. 13 (to Prospectus dated March 8, 2019) REPRO MED SYSTEMS, INC. 11,101,697 shares of common stock 424B3 1 prospectus424b3-sup13.htm PROSPECTUS SUPPLEMENT NO. 13 TO 424(B)(3) Filed Pursuant to Rule 424(b)(3) Registration No. 333-229498 PROSPECTUS SUPPLEMENT NO. 13 (to Prospectus dated March 8, 2019) REPRO MED SYSTEMS, INC. 11,101,697 shares of common stock This prospectus supplement No. 13 supplements and amends the prospectus dated March 8, 2019, as supplemented by prospectus supplement No. 1,
November 14, 2019	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 12, 2019 REPRO MED SYSTEMS, INC.
November 6, 2019	424B3	PROSPECTUS SUPPLEMENT NO. 12 (to Prospectus dated March 8, 2019) REPRO MED SYSTEMS, INC. 11,101,697 shares of common stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-229498 PROSPECTUS SUPPLEMENT NO. 12 (to Prospectus dated March 8, 2019) REPRO MED SYSTEMS, INC. 11,101,697 shares of common stock This prospectus supplement No. 12 supplements and amends the prospectus dated March 8, 2019, as supplemented by prospectus supplement No. 1, dated April 29, 2019, as further supplemented by prospectus supplement No.
November 6, 2019	10-Q	KRMD / Repro Med Systems, Inc. 10-Q - Quarterly Report - FORM 10-Q QUARTERLY REPORT FOR 09-30-2019 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2019 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 0-12305 R

KRMD / KORU Medical Systems, Inc. - تصريحات هيئة الأوراق المالية والبورصات، التقرير السنوي، بيان الوكيل

الإحصائيات الأساسية

SEC Filings

SEC Filings (Chronological Order)